Group One Trading’s Aurinia Pharmaceuticals AUPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $285K | Buy |
+19,219
| New | +$281K | ﹤0.01% | 3849 |
|
|
2025
Q3 | – | Sell |
-6,291
| Closed | -$68.7K | – | 8385 |
|
|
2025
Q2 | $53.3K | Sell |
6,291
-54,905
| -90% | -$440K | ﹤0.01% | 5526 |
|
|
2025
Q1 | $492K | Sell |
61,196
-11,698
| -16% | -$94.8K | ﹤0.01% | 3097 |
|
|
2024
Q4 | $655K | Sell |
72,894
-277,519
| -79% | -$2.26M | ﹤0.01% | 2950 |
|
|
2024
Q3 | $2.57M | Buy |
+350,413
| New | +$2.17M | 0.01% | 1527 |
|
|
2024
Q2 | – | Sell |
-377,322
| Closed | -$1.99M | – | 6695 |
|
|
2024
Q1 | $1.89M | Sell |
377,322
-301,518
| -44% | -$2.05M | 0.01% | 1521 |
|
|
2023
Q4 | $6.1M | Buy |
678,840
+94,458
| +16% | +$778K | 0.02% | 988 |
|
|
2023
Q3 | $4.54M | Buy |
584,382
+217,289
| +59% | +$2.12M | 0.02% | 996 |
|
|
2023
Q2 | $3.55M | Buy |
367,093
+43,761
| +14% | +$454K | 0.01% | 1234 |
|
|
2023
Q1 | $3.54M | Buy |
323,332
+6,736
| +2% | +$59.3K | 0.01% | 1067 |
|
|
2022
Q4 | $1.37M | Sell |
316,596
-149,093
| -32% | -$865K | ﹤0.01% | 2152 |
|
|
2022
Q3 | $3.5M | Sell |
465,689
-2,051
| -0.4% | -$17.8K | 0.01% | 1456 |
|
|
2022
Q2 | $4.7M | Buy |
467,740
+83,795
| +22% | +$937K | 0.01% | 1339 |
|
|
2022
Q1 | $4.75M | Buy |
383,945
+355,207
| +1,236% | +$5.49M | ﹤0.01% | 1583 |
|
|
2021
Q4 | $657K | Sell |
28,738
-27,349
| -49% | -$648K | ﹤0.01% | 3816 |
|
|
2021
Q3 | $1.24M | Sell |
56,087
-225,564
| -80% | -$3.58M | ﹤0.01% | 3178 |
|
|
2021
Q2 | $3.65M | Buy |
281,651
+120,178
| +74% | +$1.53M | ﹤0.01% | 2008 |
|
|
2021
Q1 | $2.1M | Sell |
161,473
-156,483
| -49% | -$2.27M | ﹤0.01% | 2415 |
|
|
2020
Q4 | $4.4M | Sell |
317,956
-25,137
| -7% | -$366K | 0.01% | 1381 |
|
|
2020
Q3 | $5.05M | Buy |
343,093
+73,862
| +27% | +$1.07M | 0.02% | 912 |
|
|
2020
Q2 | $4.38M | Buy |
269,231
+50,957
| +23% | +$816K | 0.02% | 894 |
|
|
2020
Q1 | $3.17M | Buy |
218,274
+47,551
| +28% | +$839K | 0.03% | 766 |
|
|
2019
Q4 | $3.46M | Buy |
170,723
+103,767
| +155% | +$956K | 0.02% | 901 |
|
|
2019
Q3 | $358K | Buy |
66,956
+54,710
| +447% | +$331K | ﹤0.01% | 2620 |
|
|
2019
Q2 | $81K | Buy |
12,246
+7,887
| +181% | +$50.3K | ﹤0.01% | 3499 |
|
|
2019
Q1 | $28K | Sell |
4,359
-47,894
| -92% | -$318K | ﹤0.01% | 3873 |
|
|
2018
Q4 | $356K | Sell |
52,253
-63,236
| -55% | -$365K | ﹤0.01% | 2234 |
|
|
2018
Q3 | $767K | Buy |
115,489
+35,699
| +45% | +$200K | 0.01% | 1914 |
|
|
2018
Q2 | $449K | Sell |
79,790
-67,061
| -46% | -$374K | ﹤0.01% | 2379 |
|
|
2018
Q1 | $762K | Sell |
146,851
-80,414
| -35% | -$430K | 0.01% | 1717 |
|
|
2017
Q4 | $1.03M | Sell |
227,265
-34,598
| -13% | -$192K | 0.01% | 1677 |
|
|
2017
Q3 | $1.64M | Buy |
261,863
+26,396
| +11% | +$166K | 0.01% | 1197 |
|
|
2017
Q2 | $1.44M | Buy |
235,467
+182,416
| +344% | +$1.23M | 0.02% | 1183 |
|
|
2017
Q1 | $389K | Buy |
+53,051
| New | +$245K | ﹤0.01% | 2025 |
|
Other funds holding AUPH
TCM
NMC
Group One Trading's AUPH Position: Q1 2026 in Review
Group One Trading opened a new position in Aurinia Pharmaceuticals (AUPH) in Q1 2026: 19,219 shares worth $285K. The stake represents ﹤0.01% of the portfolio and ranks #3849 among its holdings. This is a return to the name: Group One Trading previously reported a position in AUPH as recently as Q2 2025.
Group One Trading first reported a position in AUPH in Q1 2017 and has held it in 34 quarters since. The position peaked at $6.1M in Q4 2023. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.
- Group One Trading held 19,219 shares of Aurinia Pharmaceuticals worth $285K as of Q1 2026.
- Aurinia Pharmaceuticals was a new Group One Trading position in Q1 2026.
- Aurinia Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #3849 holding.
- Group One Trading first reported a position in Aurinia Pharmaceuticals in Q1 2017 and has held it in 34 quarters since.
- Group One Trading's Aurinia Pharmaceuticals position peaked at $6.1M in Q4 2023.
- 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.
Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.